‘Pulsed’ vitamin D drug could transform advanced prostate cancer treatment

November 9, 2006
Research and Development

American biotech company Novacea says it could be on the brink of revolutionising the prostate cancer market if phase III …

Abbott buys cholesterol drug specialists Kos

November 9, 2006
Sales and Marketing

Abbott is to pay $3.7 billion for Kos, the specialist US pharma company which has developed a number of major …

Novartis to be first pharma to conduct R&D in China

November 7, 2006
Research and Development Asia, China, Novartis, em

Novartis is to open a major, new pharmaceutical research and development centre in China, becoming the first company in the …

Once-a-day colitis drug could take on the leaders

November 7, 2006
Sales and Marketing

Shire is hoping its new, one-a-day treatment approach for ulcerative colitis (UC) will give the market leaders a run for …

First class relationships

November 6, 2006
Medical Communications, Sales and Marketing industry relations, key opinion leaders, pharma

Pharma goes 'no frillls'Provocative headlines drawing attention to inappropriate behaviour and misconduct in the medical and pharmaceutical professions have been …

New drive to cut millions from branded sales on NHS

November 3, 2006
Sales and Marketing generics

Some of the UK's top selling medicines are to be targeted in a new NHS drive to cut millions from …

New clinical trials agreement to improve UK research

November 3, 2006
Research and Development

The Department of Health has revised its routine contract for industry-funded NHS clinical trials as a way of improving their …

Teva and Schering-Plough UK to collaborate on bowel drug

November 3, 2006
Sales and Marketing

Teva has signed a deal with Schering-Plough UK to co-promote its ulcerative colitis and Crohn's disease treatment, Mesren.Teva hopes that …

UK industry launches ‘manifesto’ to speed uptake of new medicines

November 2, 2006
Sales and Marketing

Pharmaceutical industry organisation, the ABPI, has launched a new campaign to increase the uptake of new medicines in the UK, …

NHS staff unite in protest against government policies

November 1, 2006

 NHS employees from across England gathered in Westminster to protest against government reforms and cuts to the health service, which …

GSK suffers pipeline setbacks

November 1, 2006
Research and Development

 A series of problems with GlaxoSmithKline's late stage product pipeline has taken the shine off its third quarter figures.The company …

Pharma’s evolving relationship with NICE

November 1, 2006
Research and Development, Sales and Marketing NHS, NICE, approval process, fast track, healthcare

Back when New Labour was only halfway through its first term of office and when the Millennium Bug was feared …

Has pharma got the feelgood factor?

October 30, 2006
Business Services HR, recruitment

People are expecting more from their jobs than they ever have before. The concept of a job for life – …

Modified mice could speed safe drug discoveries

October 27, 2006
Research and Development

 CXR Biosciences, based in Scotland, and Artemis Pharmaceuticals in Germany, have been granted licences to sell their genetically modified mice, …

Protest against NHS cuts gathers momentum

October 26, 2006

 Protests against planned cuts to NHS services are taking place around the UK, with anger rising in a number of …

Most PCTs not funding Pfizer’s Macugen

October 26, 2006

 Patients with wet, age-related macular degeneration are being denied access to the first of a new class of treatment for …

Bristol-Myers Squibb suffers at hands of generic Plavix

October 26, 2006
Sales and Marketing

Figures show that the launch of a generic competitor to Plavix in the US dealt a serious blow to Bristol-Myers …

Takeda launches Actos combination in UK

October 26, 2006
Sales and Marketing

 Takeda has expanded its type II diabetes portfolio in the UK with the launch of Competact, a combination of the …

Cerovive failure another blow for AstraZeneca

October 26, 2006
Research and Development, Sales and Marketing AstraZeneca, Cerovive, neuroscience

 A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned …

Lilly underlines its position as major biotech company

October 25, 2006
Research and Development

Eli Lilly has opened the first phase of a $560 million expansion to its US biotech research complex.The news comes …

The Gateway to Local Adoption Series

Latest content